GlassScriptPhysician profile
Andrew N Blechman
NPI 1841266921
$3,782.90
in general payments reported to CMS, 2019-2025
19 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $62.14 · 2021: $89.41 · 2022: $1,369 · 2023: $260 · 2024: $1,504 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $980 · Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $980.47 |
| Food and Beverage | $910.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,357.57 | 2021-2025 | Da Vinci Surgical System |
| Astellas Pharma US INC | $316.74 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $196.45 | 2021-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Bayer Healthcare Pharmaceuticals INC. | $182.98 | 2019-2024 | |
| Abbvie INC. | $150.40 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $132.25 | 2023-2025 | |
| Organon LLC | $81.26 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $57.97 | 2019-2022 | |
| Pfizer INC. | $56.06 | 2023-2024 | |
| Exeltis, USA INC. | $53.35 | 2019-2022 | |
| Evofem Biosciences, INC. | $47.77 | 2022-2025 | Phexxi, Solosec, Phexx |
| Duchesnay USA Incorporated | $27.62 | 2019 | |
| Merck Sharp & Dohme LLC | $26.86 | 2019 | |
| Coopersurgical, INC. | $25.80 | 2020-2024 | Paragard T 380a |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 | |
| Sumitomo Pharma America, INC. | $13.93 | 2023 | Myfembree |
| Abbott Laboratories | $13.59 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Blechman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.